Sunday November 23, 2014 Search
Weather | Athens
18o C
10o C
News
Business
Comment
Life
Sports
Community
Survival Guide
Greek Edition
Drugmakers seek EU deal to keep supplies flowing

The head of Europe's drug industry has written to EU leaders ahead of their summit this week seeking major concessions to help keep supplies of medicines flowing to crisis-hit countries like Greece and Spain.

Faced with deep price cuts and billions of euros in unpaid bills, companies want two special measures to prevent discounts offered in southern Europe from being exported to rich states in the north, where governments can afford to pay for innovation.

In a forthright letter, GlaxoSmithKline Chief Executive Andrew Witty, who heads Europe's pharmaceuticals association, says failure to ring-fence austerity cuts will undermine a sector that provides 660,000 European jobs.

"In these extraordinary times for Europe, its economies and its citizens, business as usual - cost-containment policies that create market distortions - will drive investment elsewhere, Witty said.

Reuters reviewed a copy of his letter sent to European Union leaders, Commission President Jose Manuel Barroso and Council President Herman Van Rompuy ahead of the June 28-29 summit.

The euro crisis has caught drugmakers between a rock and a hard place: they are under moral pressure to maintain supply to avert a health catastrophe, yet face financial losses.

The strain is starting to tell. Germany's Biotest, a small supplier of blood products, became the first drugmaker to pull out of Greece a week ago due to unpaid debts.

Greece's healthcare system is floundering under a tangle of unpaid bills. Industry figures show less than 1 percent of drug sales to the Greek state for the first quarter of 2012 have been paid off and the total is only 34 percent for the whole of 2011.

Big international drug companies have so far stuck with difficult markets such as Greece, although some like Roche and Novo Nordisk are demanding cash on delivery in certain cases. But Witty says they need support.

In Greece, Ireland, Italy, Portugal and Spain alone, drug companies have contributed more than 7 billion euros ($8.8 billion) to balancing health budgets through exceptional price cuts and discounts in 2010 and 2011, Witty wrote in his letter.

The overall impact is still greater because governments across Europe - and, indeed, across the world - refer to prices in southern Europe when setting their own drug prices.

Low prices in southern Europe have also helped suck medicines out of the region as wholesalers re-export drugs to countries, like Germany, where prices are higher.

To counter the problem, EU member states should agree to exclude from their reference pricing baskets any countries undergoing fiscal restructuring programs, according to the European Federation of Pharmaceutical Industries and Associations (Efpia), of which Witty is president.

Efpia also wants the EU to accept a temporary ban on the re-export of medicines from states that are fighting to rebalance public finances. This could help prevent supply shortages but it is a big ask, since the Commission closely guards the right to such free movement of goods under EU laws.

"We're asking the heads of state to help us, but by helping us they are also helping themselves, Richard Bergstrom, the Brussels-based director general of Efpia, said in a telephone interview.

"That would unlock the potential for us to be more creative with governments in meeting their needs, particularly for those countries undergoing structural programs."

Witty's letter said Efpia firms had worked very hard in the member states that have had the biggest challenges to try and ensure continuity of supply.

This includes weighing emergency plans to keep drugs flowing into Greece if it should crash out of the euro, industry sources said last month.

In return for such cooperation, drugmakers want a better return in richer countries. Executives from Pfizer, Bayer and GSK have all complained in recent months that Europe is undermining drug research by not paying its fair share relative to the United States and Japan.

There is particular frustration at drug vetting systems in countries like Germany and Britain, which often stop pricey medicines from being offered on state health systems.

Supporters of such cost-effectiveness regimes, however, say they are a counterbalance to profit-driven drug companies, which too often slap high prices on new products with few clinical advantages.

[Reuters]

ekathimerini.com , Monday June 25, 2012 (13:56)  
Cyprus on agenda in Biden visit to Istanbul
PASOK nixes Papandreou leadership challenge
Troika tests govt nerves as budget rift persists
Climate change to hit farming, Greek coastline
ANALYSIS
Athens deserves slack from creditors
Talks between the government and the troika about the pending review of the Greek economic policy program have stalled over a number of issues, most prominently next years fiscal gap. Altho...
Transfer tax to be based on actual property cost, not objective value
The government intends to provide a boost to the local real estate market by reducing the tax on property transactions as of 2015, with the aim of attracting foreign investors by cutting the...
Inside Business
INTERVIEW
Tokyo hopes to change the world
The 2020 Summer Olympic and Paralympic Games in Tokyo will serve as a springboard for the rebuilding of Japans image and economy following the triple blow of the earthquake, tsunami and nuc...
BASKETBALL
Big win for Greens, tight one for Reds
Panathinaikos scored a crucial as well as emphatic away win at Turow on Thursday that should see it qualify from its tough group to the top 16 of the Euroleague, while Olympiakos saw off vis...
Inside Sports
COMMENTARY
Extremism from a bygone era
There are times when we seem to be overcome by self-destructive madness. I hear various commentators and politicians speaking in extreme terms of a junta, of defections, gallows, collaborato...
EDITORIAL
No call for more games
Psychological warfare has been a part of the negotiations between the troika and Athens from the very start of the crisis. But the situation is much different now and troika decision-makers ...
Inside Comment
SPONSORED LINK: FinanzNachrichten.de
SPONSORED LINK: BestPrice.gr
RECENT NEWS
1. Athens deserves slack from creditors
2. Transfer tax to be based on actual property cost, not objective value
3. Key general meeting at OLP on Tuesday
4. Agenda
5. Carlsberg to use Greece as regional junction
6. Cyprus on agenda in Biden visit to Istanbul
more news
Today
This Week
1. Extremism from a bygone era
2. No call for more games
3. Carlsberg to use Greece as regional junction
4. Agenda
5. Transfer tax to be based on actual property cost, not objective value
6. Key general meeting at OLP on Tuesday
Today
This Week
1. Double quake on Atalanti fault line rattles Greek capital [Update]
2. Greece and Poland switch roles as young Greeks head to vibrant Eastern European country for better prospects
3. Biden heads to Istanbul amid tension over Cyprus EEZ violation
4. Anti-junta uprising anniversary to be marked amid tight security
5. Carlsberg takes control of Greek brewer Olympic Brewery [Update]
6. Every age has its collaborators
Find us ...
... on
Twitter
... on Facebook
About us  |  Subscriptions  |  Advertising  |  Contact us  |  Athens Plus  |  RSS  |   
Copyright 2014, H KAΘHMEPINH All Rights Reserved.